Peptomyc Alternatives & Competitors
12 companies similar to Peptomyc — Developing Peptides to treat Cancer
Companies similar to Peptomyc
FogPharma
Until everything is druggable.
Kronos Bio
We’re focused on creating a world where no life is cut short by cancer or other serious di...
Myricx Bio
Developing a new class of ADCs based on NMT inhibition to treat cancer
Incyclix Bio
Regaining Cell Cycle Control
Rival Readout
Competing with Peptomyc? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Sumitomo Pharma Oncology
is part of Sumitomo Pharma America as of July 2023
PIC Therapeutics
Modulating Oncogene Translation to Dramatically Improve Cancer Patient Outcomes
Vicinitas Therapeutics
Advancing a one-of-a-kind protein stabilization platform to develop novel therapeutics for...
Cybrexa Therapeutics
Changing the paradigm for cancer treatment through the development of antigen-independent...
Breakpoint Therapeutics
Modulating DNA damage responses to cure cancer
Senex Biotechnology. Inc.
Preventing Adaptive Drug Resistance and Cancer Metastasis
TransCode Therapeutics, Inc.
Delivering a cancer-free future
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
About Peptomyc
Peptomyc, with its slogan "Developing Peptides to treat Cancer", is prominently positioned at the intersection of Biotechnology and Health Care. Founded in 2014, this Spain-based company is pioneering a new class of cell-penetrating peptides (CPPs) aimed at targeting the notorious Myc oncoprotein, a formidable contribu...
Development of MYC inhibitory drugs, Clinical trial management, Biotechnological research and innovation
Cancer patients with abnormal MYC activity, Healthcare providers, Oncology research institutions, Pharmaceutical partners
Cell Penetrating Peptides, Myc Oncoprotein, Cancer Treatment, Omomyc, Drug Development, Oncology, Myc Inhibition, Precision Medicine, Glioblastoma, Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, Cancer Resistance, Novel Therapeutics, VHIO Collaboration
B2B, B2B2C, Platform
Licensing, Product Sales, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Peptomyc: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Peptomyc on 15 Jun 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.